Lino-M Tablet 2.5 mg + 1000 mg is a combination oral antidiabetic medication that contains Linagliptin and Metformin Hydrochloride, formulated for adults with type 2 diabetes mellitus. This dual-action tablet helps improve glycemic control in patients whose blood sugar levels are inadequately managed by diet, exercise, or monotherapy with either Linagliptin or Metformin.

Linagliptin, a DPP-4 (dipeptidyl peptidase-4) inhibitor, works by increasing incretin hormone levels, which enhances glucose-dependent insulin secretion and suppresses glucagon release. Metformin Hydrochloride, a biguanide, decreases hepatic glucose production and improves peripheral insulin sensitivity. Together, they target the key pathophysiological defects of type 2 diabetes—insulin deficiency and insulin resistance—offering comprehensive glycemic management.

This combination not only reduces fasting and postprandial blood glucose but also maintains weight neutrality and lowers the risk of hypoglycemia compared to sulfonylureas or insulin therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Oral Antidiabetic – DPP-4 Inhibitor + Biguanide Combination

Indications

Lino-M Tablet 2.5 mg + 1000 mg is indicated for:

• Adults with type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise

• Patients inadequately controlled with:

  • Metformin monotherapy

  • Linagliptin monotherapy

  • Other oral antidiabetic agents where dual therapy is appropriate

• Managing both fasting and postprandial hyperglycemia

• Can be used in combination with insulin or other antidiabetic therapies under medical supervision

This combination is particularly suitable for patients who require high-dose Metformin for effective glycemic control while benefiting from Linagliptin’s incretin-based action.

Pharmacology

Linagliptin:

• Inhibits DPP-4 enzyme, preventing degradation of incretin hormones (GLP-1 and GIP)

• Enhances glucose-dependent insulin secretion

• Suppresses inappropriate glucagon secretion from pancreatic alpha cells

• Improves postprandial and fasting glucose levels

Metformin Hydrochloride:

• Reduces hepatic gluconeogenesis (liver glucose production)

• Enhances insulin sensitivity, increasing peripheral glucose uptake

• Minimal risk of hypoglycemia when used alone

Combination Effect:

• Complementary mechanisms provide superior glycemic control

• Reduces HbA1c effectively compared to monotherapy

• Weight-neutral and cardiovascular-friendly

Dosage and Administration

• Usually 1 tablet twice daily with meals, or as prescribed by a physician

• Swallow the tablet whole with water; do not crush or chew

• Dosage may require adjustment in patients with renal or hepatic impairment

• Therapy should be combined with a balanced diet and regular exercise

• Regular monitoring of blood glucose and HbA1c is recommended to assess efficacy

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Use with caution in renal impairment or risk of lactic acidosis

• Monitor kidney and liver function periodically

• Not suitable for type 1 diabetes or diabetic ketoacidosis

• May interact with other antidiabetic agents, increasing hypoglycemia risk

Possible Side Effects

• Gastrointestinal: nausea, vomiting, diarrhea, abdominal discomfort

• Headache, dizziness, or mild upper respiratory infections

• Rare: lactic acidosis (especially in renal impairment)

• Hypoglycemia may occur when combined with sulfonylureas or insulin

Contraindications

• Severe renal impairment or end-stage renal disease

• Hypersensitivity to Linagliptin, Metformin, or any formulation components

• Acute or chronic metabolic acidosis, including diabetic ketoacidosis

Pregnancy & Lactation

• Should be used only if clearly indicated

• Metformin may be continued during pregnancy under medical supervision

• Linagliptin safety during pregnancy is not established

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.